Valuation: Novacyt

Market Cap 31.47M 34.66M 29.07M 26.22M 49.5M 3.24B 51.4M 350M 139M 1.75B 130M 127M 5.52B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 33.42M 36.82M 30.87M 27.85M 52.58M 3.44B 54.59M 372M 147M 1.86B 138M 135M 5.86B EV / Sales 2026 *
1.09x
EV / Sales 2027 * 1.04x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-0.81%
1 week-2.16%
Current month-2.16%
1 month-6.82%
3 months-21.01%
6 months-17.37%
Current year+10.10%
1 week 0.42
Extreme 0.425
0.46
1 month 0.4
Extreme 0.404
0.48
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Date Insider Type Main position Quantity % Market Cap. Importance
3/30/26 Buy

Chief Executive Officer

1,792 0.0025%
3/30/26 Buy

Chairman

15,228 0.0216%
3/30/26 Buy

Chairman

56,732 0.0803%
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%-2.16%-1.03%-27.16% 34.66M
+1.15%-2.81%+55.79%+71.12% 66.37B
+1.54%-0.85%+10.07%+92.59% 58.86B
+0.90%+0.93%+26.57%+87.51% 55.22B
+0.48%-2.53%+9.73%+121.14% 47.21B
-2.69%-6.38%+19.19%+25.79% 42.45B
-0.70%+4.93%+17.77%+45.03% 36.44B
-2.50%-15.73%+135.31%+662.73% 35.19B
+0.51%-0.93%+84.13%+58.92% 32.66B
-0.83%+1.98%-38.27%+390.98% 26.73B
Average -0.28%-1.94%+31.93%+152.86% 40B
Weighted average by Cap. +0.03%-2.18%+35.32%+147.45%

Financials

2026 *2027 *
Net sales 30.52M 33.63M 28.2M 25.44M 48.02M 3.14B 49.86M 340M 134M 1.7B 126M 124M 5.36B 34.86M 38.4M 32.2M 29.05M 54.85M 3.59B 56.95M 388M 153M 1.94B 144M 141M 6.12B
Net income - -
Net Debt 1.96M 2.15M 1.81M 1.63M 3.08M 201M 3.2M 21.77M 8.61M 109M 8.08M 7.91M 343M 4.84M 5.33M 4.47M 4.04M 7.62M 498M 7.91M 53.9M 21.32M 269M 20.01M 19.59M 850M
Projected Income Statement - Annual - Novacyt
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
228
Date Price Change Volume
26-11-18 €0.4305 -0.81% 33,015
26-11-17 €0.4340 -3.56% 9,057
26-11-16 €0.4500 0.00% 464,457
26-11-13 €0.4500 +4.65% 156,799
26-11-12 €0.4300 -2.27% 355,506

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Novacyt
  1. Stock Market
  2. Stocks
  3. ALNOV Stock